The treatment of acute bacterial sinusitis: No change is good medicine

Le Saux, Nicole
March 2008
CMAJ: Canadian Medical Association Journal;3/25/2008, Vol. 178 Issue 7, p865
Academic Journal
The article focuses on treating acute bacterial sinusitis. According to the author, there are clinical trials which show that majority of patients with acute bacterial sinusitis have a 50 to 70 percent chance of recovery without antibiotic therapy. The article also provides information on fluoroquinolones such as levofloxacin and moxifloxacin. Fluoroquinolones have a range of antibacterial activity which makes them useful in treating respiratory tract infections such as pneumonia and sinusitis. Information on the effectiveness of levofloxacin and ampicillin in the treatment of acute bacterial sinusitis is also provided.


Related Articles

  • Clinical and bacteriological efficacies of sitafloxacin against community-acquired pneumonia caused by Streptococcus pneumoniae: nested cohort within a multicenter clinical trial. Fujita, Jiro; Niki, Yoshihito; Kadota, Jun-ichi; Yanagihara, Katsunori; Kaku, Mitsuo; Watanabe, Akira; Aoki, Nobuki; Hori, Seiji; Tanigawara, Yusuke; Cash, Haley; Kohno, Shigeru // Journal of Infection & Chemotherapy (Springer Science & Business;Jun2013, Vol. 19 Issue 3, p472 

    We evaluated the clinical and bacteriological efficacy of oral sitafloxacin (STFX) in clinically diagnosed community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae. Additionally, we cultured these patient samples to test the minimal inhibitory concentrations (MICs) of levofloxacin...

  • Interaction Profile of Moxifloxacin. Stass, H.; Kubitza, D. // Drugs;Dec1999 Supplement 2, Vol. 58 Issue 6, p235 

    Investigates the influence of probenecid on the elimination of moxifloxacin. Methods; Results.

  • Clinical Perspectives on New Antimicrobials: Focus on Fluoroquinolones. Talan, David A. // Clinical Infectious Diseases;3/15/2001 Supplement 1, Vol. 32, pS64 

    Respiratory tract infections are the most common infectious presentation in the community and hospital settings and are a major cause of morbidity and mortality worldwide. Recently, newer fluoroquinolones have been recommended for the treatment of these infections. Among them, moxifloxacin shows...

  • THE POTENCY/EFFICACY OF THE FLUROQUINOLONES IN COMMUNITY-ACQUIRED PNEUMONIA. Mandell, Lionel A. // Managed Healthcare Executive;Jun2002 Supplement 1, Vol. 12 Issue 6, p27 

    Examines the efficacy of the fluoroquinolones in community-acquired pneumonia. Characteristics of community-acquired pneumonia; Properties of fluoroquinolones, the quinolones antibacterial agents; Comparison of fluoroquinolones with other antibacterial agents.

  • Ofloxacin Once Daily Versus Twice Daily in Community-Acquired Pneumonia. Krcméry Jr, V. // Drugs;Dec1999 Supplement 2, Vol. 58 Issue 6, p282 

    Reports on the use of quinolone ofloxacin in the treatment of community-acquired pneumonia. Patients and methods; Results and discussion.

  • Moxifloxacin.  // Reactions Weekly;Sep2015, Vol. 1568 Issue 1, p202 

    The article presents a case study of a 78-year-old male patient who developed acute confusional syndrome during moxifloxacin treatment.

  • Variation in the mutation frequency determining quinolone resistance in Chlamydia trachomatis serovars L2 and D. Jan Rupp; Werner Solbach; Jens Gieffers // Journal of Antimicrobial Chemotherapy (JAC);Jan2008, Vol. 61 Issue 1, p91 

    : Objectives Quinolone resistance of chlamydiae is supposed to be extremely rare. To assess the risk for the emergence of chlamydial quinolone resistance, we analysed the occurrence of resistant mutants in a quantitative perspective. : Methods Infectious elementary bodies of Chlamydia...

  • Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China. Ying-yuan Zhang; Hai-hui Huang; Zhen-yi Ren; Hong-guang Zheng; Yun-song Yu; Xiao-ju Lü; Zu-ke Xiao; Hui-fen Yang; Qing-yu Xiu; Bao-yuan Chen; Hong-mei Yue; Qing-lin Hao; Jian-an Huang; Hui Ma; Wei Xiao; Dong-yang Guo; Bin Si; Sheng-hua Sun; Wei Zhang; Qi-hao Li // Journal of Infection & Chemotherapy;Oct2009, Vol. 15 Issue 5, p301 

    Abstract  Levofloxacin (LVFX), a fluoroquinolone agent, has a broad spectrum that covers Gram-positive and -negative bacteria and atypical pathogens. It demonstrates good clinical efficacy in the treatment of various infections, including lower respiratory tract infections (LRTIs) and...

  • SINUS TISSUE CONCENTRATION OF MOXIFLOXACIN AFTER A SINGLE ORAL DOSE. Dinis, Paulo Borges; Maria Conceiç, ão; Silva, Nuno; Martins, Maria Luz; Morais, José Guimarães // Annals of Otology, Rhinology & Laryngology;Feb2004, Vol. 113 Issue 2, p142 

    Moxifloxacin is a new fluoroquinolone antimicrobial approved for the treatment of acute bacterial rhinosinusitis. In order to assess its distribution pattern into the paranasal sinuses, and specifically to evaluate how the histopathologic changes associated with chronic inflammation affect its...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics